Gryphon Financial Partners LLC Increases Holdings in Eli Lilly and Company $LLY

Gryphon Financial Partners LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,668 shares of the company’s stock after buying an additional 465 shares during the period. Gryphon Financial Partners LLC’s holdings in Eli Lilly and Company were worth $5,213,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LLY. Townsend Asset Management Corp NC ADV increased its stake in shares of Eli Lilly and Company by 3.9% in the 1st quarter. Townsend Asset Management Corp NC ADV now owns 2,256 shares of the company’s stock worth $2,075,000 after acquiring an additional 85 shares during the last quarter. Astra Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 5.1% in the first quarter. Astra Wealth Partners LLC now owns 332 shares of the company’s stock valued at $305,000 after purchasing an additional 16 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $2,276,000. Assetmark Inc. increased its position in Eli Lilly and Company by 2.6% during the first quarter. Assetmark Inc. now owns 60,441 shares of the company’s stock worth $55,592,000 after purchasing an additional 1,558 shares during the last quarter. Finally, NovaPoint Capital LLC increased its position in Eli Lilly and Company by 5.6% during the first quarter. NovaPoint Capital LLC now owns 5,818 shares of the company’s stock worth $5,351,000 after purchasing an additional 311 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. Morgan Stanley raised their target price on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Finally, Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,283.64.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,178.01 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45. The firm’s 50 day moving average price is $1,118.87 and its 200 day moving average price is $1,036.80. The company has a market cap of $1.11 trillion, a P/E ratio of 41.85, a PEG ratio of 1.47 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the business posted $3.34 EPS. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts forecast that Eli Lilly and Company will post 34.55 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.